The deal is proceeding toward the July 9 vote with no change in terms. For PCSC holders, the key variable is redemption levels — high redemptions could jeopardize the minimum $250M condition or leave minimal float. Post-close, the stock will reflect Freenome's fundamentals: no revenue, heavy cash burn, and an uncertain FDA path for CRC screening. Monitor the redemption deadline (July 7) and the proxy vote outcome.
Price Chart
Executive Summary
This S-4/A is an administrative amendment to the registration statement for PCSC's business combination with Freenome, adding inline XBRL exhibits and updated consents. The deal terms remain unchanged: Freenome, a pre-revenue cancer diagnostics firm with a $1.4B accumulated deficit and no approved products, will go public via the SPAC merger. Public SPAC shareholders face extreme dilution, dropping from 76.3% ownership to as low as 1.9% post-close. The Extraordinary General Meeting is scheduled for July 9, 2026.
Key Facts
- Filing is Amendment No. 3 to S-4; adds iXBRL and updated consents (Exhibits 23.1, 23.2, 99.1) with no substantive changes to deal terms.
- PIPE Financing of $240.0M (24M shares at $10.00/share) committed; aggregate proceeds condition requires at least $250M at close.
- Freenome has $1.4B accumulated deficit, net losses of $63.6M (Q1 2026), $219.3M (2025), and $274.4M (2024); no approved products or material revenue.
- Public SPAC shareholders owning 76.3% of PCSC pre-deal will hold only 1.9%–6.97% of New Freenome post-close depending on redemptions.
- Per-share redemption price estimated at ~$10.82; ~$85.2M remains in trust account after extension-related redemptions.
- Extraordinary General Meeting to vote on the Business Combination set for July 9, 2026; extension to complete deal by June 13, 2027 already approved.
- Freenome's SimpleScreen CRC PMA received a major deficiency letter; complete response submitted in April 2026; FDA decision and commercial timeline uncertain.
Financial Impact
PIPE of $240M plus trust proceeds (~$85M) net of redemptions and expenses; Freenome burned $63.6M in Q1 2026 and expects continued losses.
Risk Factors
- Failure to meet the $250M minimum aggregate proceeds condition could kill or delay the deal.
- Extreme dilution for non-redeeming SPAC shareholders.
- Freenome has no approved products, negative cash flow, and faces uncertain FDA approval for its lead CRC test.
- Nasdaq listing of New Freenome common stock is a condition but not yet confirmed; may be waived without notice.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001140361-26-024950 |
| Document: ny20061080x14_ex99-1.htm | 0001140361-26-024950 |
| Document: ny20061080x14_ex23-1.htm | 0001140361-26-024950 |
| Document: ny20061080x14_ex23-2.htm | 0001140361-26-024950 |
| Document: 0001140361-26-024950-index-headers.html | 0001140361-26-024950 |
| Document: 0001140361-26-024950-index.html | 0001140361-26-024950 |
| Document: 0001140361-26-024950.txt | 0001140361-26-024950 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 22, 2026 13w ago | 3 | $12.01 | awaiting T+5 | — | — |
Jul 22, 2026 13w ago | 3 | $12.01 | awaiting T+5 | — | — |
Jul 20, 2026 14w ago | 25-NSE | $12.01 | awaiting T+5 | — | — |
Jul 9, 2026 15w ago | 425 | $10.90 $12.00 | ▲ +10.09% | ▲ +10.22% | — |
Jul 9, 2026 15w ago | 425 / 8-K | $10.90 $12.00 | ▲ +10.09% | ▲ +10.22% | — |
Jun 18, 2026 18w ago | 425 | $11.01 $10.93 | ▼ −0.73% | ▲ +1.34% | — |
Jun 18, 2026 18w ago | 8-K | $11.01 $10.93 | ▼ −0.73% | ▲ +1.34% | — |
Jun 18, 2026 18w ago | EFFECT | $11.09 $10.96 | ▼ −1.17% | ▲ +0.49% | — |
Jun 11, 2026 19w ago | S-4/A | $11.40 $11.09 | ▼ −2.72% | ▼ −3.39% | — |
Jun 10, 2026 19w ago | 425 | $11.27 $11.16 | ▼ −0.98% | ▼ −1.41% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers